CJC-1295 without DAC: A Laboratory Research Reference

CJC-1295 without DAC is the unmodified form of a synthetic growth hormone–releasing hormone (GHRH) analogue. It is studied in laboratory research for its interaction with the GHRH receptor and the downstream promotion of growth hormone release in experimental models. Unlike the "with DAC" form, it carries no albumin-binding Drug Affinity Complex, which gives it a shorter circulating duration.

This page is a non-promotional scientific reference for researchers. It does not provide performance, anti-ageing, therapeutic, or human-use guidance. CJC-1295 without DAC supplied by Bulk Aussie Peptides is for laboratory research purposes only.

Chemical Identity

CJC-1295 is a GHRH analogue bearing a substitution that improves its stability relative to the native hormone. In the "without DAC" form, no additional albumin-binding complex is attached, so the peptide retains a pharmacokinetic profile closer to that of a conventional short-acting GHRH analogue. The presence or absence of the DAC group is the functional distinction from the long-acting form.

This distinction matters in research design: the without-DAC form is typically used where a shorter duration of receptor activation is desired, or to isolate the effects of the DAC group itself. The two are compared in a dedicated comparison.

Molecular Characteristics

• Classification: a growth hormone–releasing hormone (GHRH) analogue without an albumin-binding DAC group.
• Sequence basis: derived from native GHRH with a stability-improving substitution.
• Molecular weight: reported in Daltons (Da), without the additional mass contributed by a DAC group.
• Physical form: lyophilised (freeze-dried) powder.

Mechanism as Studied

In laboratory models, CJC-1295 without DAC binds to the GHRH receptor and promotes growth hormone release with a shorter duration of action than the DAC-modified form. This makes it useful for studying the relationship between receptor-exposure duration and downstream growth hormone response. Findings remain preclinical.

Areas of Scientific Research

• GHRH receptor pharmacology: receptor activation and downstream signalling.
• Growth hormone secretion: release in experimental models.
• Pharmacokinetic behaviour: short-acting versus long-acting GHRH analogue profiles.

These investigations are conducted in vitro or in approved animal research models under institutional oversight.

Analytical Testing

CJC-1295 without DAC is characterised using:

• HPLC for purity assessment.
• Mass spectrometry for identity confirmation by molecular mass.

See how to read a peptide Certificate of Analysis for interpretation guidance.

References and Further Reading

• CJC-1295 without DAC and the GHRH analogue family. (Preclinical research literature on growth-hormone–releasing hormone analogues.)
• CJC-1295 DAC vs No DAC — a detailed comparison.
• Reading a Peptide Certificate of Analysis.